"When my 85-year-old grandad is asking me if I've cheated on my girlfriend because he's seen it repeatedly on the news, that's where I draw the line on what's acceptable and what's not," he said in a statement on Instagram.
"When my 85-year-old grandad is asking me if I've cheated on my girlfriend because he's seen it repeatedly on the news, that's where I draw the line on what's acceptable and what's not," he said in a statement on Instagram.
The pitch behind YieldMax Magnificent 7 Fund of Option Income ETFs (NYSEARCA:YMAG) is intuitive: own all seven Magnificent Seven names through a single ticker, collect a fat weekly distribution, and let YieldMax run synthetic covered calls in the background. YMAG bundles seven single-stock YieldMax sleeves on Apple, Microsoft, Alphabet, Amazon, Meta, NVIDIA, and Tesla into ... YMAG Bundles YieldMa...
The pitch behind YieldMax Magnificent 7 Fund of Option Income ETFs (NYSEARCA:YMAG) is intuitive: own all seven Magnificent Seven names through a single ticker, collect a fat weekly distribution, and let YieldMax run synthetic covered calls in the background. YMAG bundles seven single-stock YieldMax sleeves on Apple, Microsoft, Alphabet, Amazon, Meta, NVIDIA, and Tesla into ... YMAG Bundles YieldMax’s Magnificent Seven Strategy Into One Ticker, And the NAV Decay Compounds Across All Seven
Key Points Intuitive Surgical's stock is trading near 52-week lows. The stock is down 30% from its most recent high-water mark. Intuitive Surgical's business remains strong, and the stock has seen swings like this many times before. 10 stocks we like better than Intuitive Surgical › Intuitive Surgical (NASDAQ: ISRG) is in its own bear market, down more than 30% from its early 2025 highs. Wall Stre...
Key Points Intuitive Surgical's stock is trading near 52-week lows. The stock is down 30% from its most recent high-water mark. Intuitive Surgical's business remains strong, and the stock has seen swings like this many times before. 10 stocks we like better than Intuitive Surgical › Intuitive Surgical (NASDAQ: ISRG) is in its own bear market, down more than 30% from its early 2025 highs. Wall Street analysts are still upbeat on the future, however, with an average price target of $570. That would represent a full recovery and a gain of more than 30% from recent depressed levels. If history is any guide, Wall Street analysts are likely correct about the stock's recovery potential. And that remains true even though the price-to-earnings ratio is a lofty 51x. Here's what you need to know if you are thinking about buying Intuitive Surgical today. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Intuitive Surgical has a strong business model Intuitive Surgical is a medical device company. That said, it is focused entirely on surgical robots, with its da Vinci surgical system. It is an industry leader in the space, with 11,395 systems installed worldwide at the end of the first quarter of 2026, up 12% from the prior year. There is clearly a strong demand for the da Vinci system. The number of surgeries performed by a da Vinci robot rose 17% year over year. That highlights the broad demand for robotic surgery that Intuitive Surgical is leaning into. And it shows why the company's true business strength isn't selling robots, but selling instruments, accessories, and services. Together, these three revenue items make up roughly 75% of the top line. They are annuity-like income streams that get more attractive every time the company sells another da Vinci system. The long-term outlook for the business is str...
Key Points Patient Capital sold 2,794,343 Mattel shares last quarter. The quarter-end stake value fell by $55.44 million, reflecting what filings show was a full exit. The Mattel sale represented a 1.86% shift in Patient Capital’s reported U.S. equity assets under management. 10 stocks we like better than Mattel › Patient Capital Management fully exited its position in Mattel (NASDAQ:MAT) during t...
Key Points Patient Capital sold 2,794,343 Mattel shares last quarter. The quarter-end stake value fell by $55.44 million, reflecting what filings show was a full exit. The Mattel sale represented a 1.86% shift in Patient Capital’s reported U.S. equity assets under management. 10 stocks we like better than Mattel › Patient Capital Management fully exited its position in Mattel (NASDAQ:MAT) during the first quarter, selling 2,794,343 shares in a trade estimated at $50.92 million based on quarterly average pricing, according to a May 14, 2026, SEC filing. What happened According to a SEC filing dated May 14, 2026, Patient Capital Management sold all 2,794,343 shares of Mattel during the first quarter. The sale’s estimated value was $50.92 million based on the average closing price over the quarter. The quarter-end change in position valuation, including price effects, was $55.44 million. The fund now holds no shares of Mattel. What else to know Top holdings after the filing: NASDAQ: RPRX: $174.79 million (6.5% of AUM) NYSE: C: $160.35 million (6.0% of AUM) NASDAQ: GOOGL: $153.56 million (5.7% of AUM) NASDAQ: AMZN: $136.30 million (5.1% of AUM) NYSE: QXO: $131.64 million (4.9% of AUM) As of May 13, 2026, shares of Mattel were priced at $14.82, down 24% over the past year and underperforming the S&P 500, which is up 28% in the same period. Company Overview Metric Value Price (as of market close 2026-05-13) $14.82 Market Capitalization $4.38 billion Revenue (TTM) $5.38 billion Net Income (TTM) $498.92 million Company Snapshot Mattel produces toys, games, and children’s entertainment products under brands such as Barbie, Hot Wheels, Fisher-Price, and American Girl, with revenues primarily generated from global toy sales and licensing. The company operates a diversified business model that includes direct-to-consumer sales, retail partnerships, and licensing arrangements with major entertainment franchises. Primary customers include children and families worldwide, with pro...
'We Outright Grabbed The Wallets': Bessent Boasts $1BN In Iran State Crypto Seized To Date Washington's economic war on Iran and its 'shadow' banking network continues, as on Friday Treasury Secretary Scott Bessent announced the US has seized $1 billion in Iranian cryptocurrency assets as part of the economic component of President Trump's Operation Epic Fury. The billion dollar figure represents ...
'We Outright Grabbed The Wallets': Bessent Boasts $1BN In Iran State Crypto Seized To Date Washington's economic war on Iran and its 'shadow' banking network continues, as on Friday Treasury Secretary Scott Bessent announced the US has seized $1 billion in Iranian cryptocurrency assets as part of the economic component of President Trump's Operation Epic Fury. The billion dollar figure represents the running total seized to date , building on prior milestones in the conflict, particularly a recent major April 2026 freeze of $344 million in USDT on the Tron blockchain. By close of April, $500 million total had been seized. And so clearly with the addition since then of some half-billion dollars more in seized digital assets, the US Treasury program has only greatly accelerated in the last several weeks. During his Friday speech before the Reagan National Economic Forum, Bessent stated : "Just outright grabbed the wallets. Some of them may be typing in right now and might not realize their wallet had been grabbed ." Assets are held "on behalf of the Iranian people" - he described, while framing that the Iranian government had 'stolen' the money from the Iranian populace. Bessent on Iran: We have seized about $1 billion of Iran's crypto — just outright grabbed the wallets. Some of them may be typing in right now and might not realize their wallet has been grabbed. This is money that's stolen from the Iranian people. pic.twitter.com/h3ycrJn1Jy — Clash Report (@clashreport) May 29, 2026 Bessent is signaling further relentless waves of OFAC wallet designations and aggressive asset forfeitures coming in the next months, as highly sanctioned Iran continues to seek alternative means of conducting financial transactions. As we've featured before , for ordinary Iranians - roughly one in six of the population - crypto served as a vital lifeline. Facing relentless rial depreciation (down nearly 90 percent since 2018), chronic inflation of 40 to 50 percent, and frequent power bla...
Key Points Needham Investment Management added 65,000 shares of nLIGHT last quarter. The quarter-end position value increased by $39.95 million, reflecting both share purchases and stock price appreciation. Post-trade, the firm held 1,922,740 shares worth $109.63 million. 10 stocks we like better than nLIGHT › On May 14, 2026, Needham Investment Management disclosed a buy of 65,000 shares of nLIGH...
Key Points Needham Investment Management added 65,000 shares of nLIGHT last quarter. The quarter-end position value increased by $39.95 million, reflecting both share purchases and stock price appreciation. Post-trade, the firm held 1,922,740 shares worth $109.63 million. 10 stocks we like better than nLIGHT › On May 14, 2026, Needham Investment Management disclosed a buy of 65,000 shares of nLIGHT (NASDAQ:LASR), an estimated $3.52 million trade based on quarterly average pricing. What happened According to a filing with the Securities and Exchange Commission dated May 14, 2026, Needham Investment Management bought 65,000 additional shares of nLIGHT in the first quarter. The estimated transaction value was $3.52 million, calculated using the average closing price for the quarter. The quarter-end position value rose by $39.95 million, a figure that includes both trading activity and stock price movements. What else to know Following the buy, nLIGHT represented 5.6% of the fund’s reportable assets under management. Top holdings after the filing: NASDAQ:LASR: $109.63 million (5.6% of AUM) NASDAQ:VICR: $84.04 million (4.3% of AUM) NYSE:VRT: $71.48 million (3.7% of AUM) NASDAQ:PDFS: $66.16 million (3.4% of AUM) NASDAQ:AIP: $64.98 million (3.3% of AUM) As of Friday, nLIGHT shares were priced at $74.12, skyrocketing nearly 400% over the past year while the S&P 500 has climbed about 28%. Company overview Metric Value Price (as of Friday) $74.12 Market Capitalization $4.2 billion Revenue (TTM) $289.84 million Net Income (TTM) ($14.73 million) Company snapshot nLIGHT designs and manufactures semiconductor and fiber lasers, fiber amplifiers, and beam control systems for industrial, microfabrication, and aerospace and defense applications. The firm generates revenue through direct product sales and advanced development contracts, serving both commercial and government markets. Its primary customers include manufacturers in the United States, China, South Korea, Europe, and defe...
RTW Investments disclosed in a May 15, 2026, SEC filing that it bought 16,010,524 shares of Erasca (NASDAQ:ERAS) , an estimated $189.23 million trade based on quarterly average pricing. According to a May 15, 2026, SEC filing , RTW Investments increased its holdings in Erasca by 16,010,524 shares during the first quarter of 2026. The estimated transaction value is $189.23 million, calculated using...
RTW Investments disclosed in a May 15, 2026, SEC filing that it bought 16,010,524 shares of Erasca (NASDAQ:ERAS) , an estimated $189.23 million trade based on quarterly average pricing. According to a May 15, 2026, SEC filing , RTW Investments increased its holdings in Erasca by 16,010,524 shares during the first quarter of 2026. The estimated transaction value is $189.23 million, calculated using the average closing price for the period. The fund’s quarter-end stake in Erasca was valued at $261.42 million, up $260.88 million from the prior quarter, a figure that incorporates both share purchases and pricing effects. Erasca is a clinical-stage biotechnology company headquartered in San Diego, California, with a focus on developing targeted therapies for cancer driven by the RAS/MAPK pathway. The company leverages a robust pipeline of oral inhibitors designed to address significant unmet needs in oncology. Erasca's strategy emphasizes innovation in precision medicine to achieve durable clinical outcomes in challenging cancer indications. Continue reading
Discovery brings death toll from chemical tank rupture in Longview to nine, with two workers still unaccounted for Crews on Friday recovered the remains of one more victim of a massive chemical tank rupture at a paper mill in Washington state, bringing the death toll to nine people and leaving two workers still unaccounted for. Among the 11 workers presumed killed in the disaster were two brothers...
Discovery brings death toll from chemical tank rupture in Longview to nine, with two workers still unaccounted for Crews on Friday recovered the remains of one more victim of a massive chemical tank rupture at a paper mill in Washington state, bringing the death toll to nine people and leaving two workers still unaccounted for. Among the 11 workers presumed killed in the disaster were two brothers who worked there together, a trivia champ and an electrician who would help his farmer neighbors cut hay. Continue reading...
On May 15, 2026, RTW Investments disclosed a major buy of Tango Therapeutics (TNGX +9.90%), acquiring 11,809,392 shares—an estimated $164.37 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, RTW Investments bought 11,809,392 shares of Tango Therapeutics (TNGX +9.90%), with the estimated transaction val...
On May 15, 2026, RTW Investments disclosed a major buy of Tango Therapeutics (TNGX +9.90%), acquiring 11,809,392 shares—an estimated $164.37 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, RTW Investments bought 11,809,392 shares of Tango Therapeutics (TNGX +9.90%), with the estimated transaction value at $164.37 million based on the quarter’s average share price. The fund’s quarter-end position value in the company increased by $265.04 million, a figure that reflects both the additional shares and the stock’s price movement. What else to know RTW Investments increased its stake in Tango Therapeutics, bringing the position to roughly 3% of its 13F reportable assets under management. Top holdings after this filing: NASDAQ:MDGL: $1.04 billion (10.4% of AUM) NASDAQ:INSM: $791.91 million (7.9% of AUM) NASDAQ:PTGX: $533.22 million (5.3% of AUM) NASDAQ:PTCT: $527.76 million (5.3% of AUM) NASDAQ:ARGX: $518.07 million (5.2% of AUM) As of Friday, shares of Tango Therapeutics were priced at $21.98, up a staggering 840% over the past year and well outperforming the S&P 500, which is up 28%. Company Overview Metric Value Market Capitalization $3 billion Revenue (TTM) $56.99 million Net Income (TTM) ($107.23 million) Company Snapshot TNGX develops targeted oncology therapies, including TNG908 for cancers with methylthioadenosine phosphorylase deletions, and additional programs addressing BRCA1/2-mutant and STK11-mutant cancers. The firm has a strategic collaboration with Gilead Sciences for the discovery, development, and commercialization of cancer therapies. It is based in Cambridge, Massachusetts, with a focus on precision medicine for genetically defined cancers. Tango Therapeutics, Inc. is a biotechnology company specializing in the discovery and development of precision cancer therapies. Leveraging synthetic lethality and strategic collaborations, the company advances a pipel...
Key Points Needham Investment Management purchased 152,500 shares of Lincoln Educational Services, with an estimated transaction value of $4.80 million based on quarterly average pricing. Meanwhile, the quarter-end position value increased by $24.80 million, reflecting both trading activity and share price appreciation. Post-trade, the fund held 1,277,500 shares valued at $51.97 million 10 stocks ...
Key Points Needham Investment Management purchased 152,500 shares of Lincoln Educational Services, with an estimated transaction value of $4.80 million based on quarterly average pricing. Meanwhile, the quarter-end position value increased by $24.80 million, reflecting both trading activity and share price appreciation. Post-trade, the fund held 1,277,500 shares valued at $51.97 million 10 stocks we like better than Lincoln Educational Services › On May 14, 2026, Needham Investment Management reported buying 152,500 shares of Lincoln Educational Services (NASDAQ:LINC), an estimated $4.80 million trade based on quarterly average pricing. What happened According to a recent filing with the Securities and Exchange Commission, Needham Investment Management increased its stake in Lincoln Educational Services by 152,500 shares during the first quarter of 2026. The estimated value of the shares acquired is approximately $4.80 million, based on the average closing price during the quarter. The fund’s quarter-end position value increased by $24.80 million, a figure that includes both trading activity and market price changes. What else to know Following the buy, Lincoln Educational Services represented 2.66% of the fund’s reportable assets under management as of March 31, 2026. Top holdings after the filing: NASDAQ:LASR: $109.63 million (5.6% of AUM) NASDAQ:VICR: $84.04 million (4.3% of AUM) NYSE:VRT: $71.48 million (3.7% of AUM) NASDAQ:PDFS: $66.16 million (3.4% of AUM) NASDAQ:AIP: $64.98 million (3.3% of AUM) As of Friday, shares of Lincoln Educational Services were priced at $46.32, up about 100% over the past year and well outperforming the S&P 500, which is up 28% in the same period. Company overview Metric Value Price (as of Friday) $46.32 Market capitalization $1.5 billion Revenue (TTM) $544.69 million Net income (TTM) $22.41 million Company snapshot Lincoln offers career-oriented post-secondary education programs in automotive technology, skilled trades, healthcare, ...